KYOWA HAK KIRIN (KY4 DU) stock market data APIs
€14.0469
0(0%)
as of February 11, 2026
Try our APIs with
free plan!
KYOWA HAK KIRIN Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for KY4.DU.
Prev. Close
14.0469
Open
14.0469
High
14.0469
Low
14.0469
52 wk Range
11.9516-15.1123
Market Cap
13 438 M
Dividends (Yield)
2.0792
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get KYOWA HAK KIRIN data using free add-ons & libraries
Get KYOWA HAK KIRIN Fundamental Data
KYOWA HAK KIRIN Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-09
- EPS/Forecast: 40.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
KYOWA HAK KIRIN News
New
Amgen Reshapes Inflammation Portfolio As Investors Weigh Cash And Pipeline Shifts
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amgen ended its collaboration with Kyowa Kirin on the exper...
Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Amgen (NasdaqGS:AMGN) ended its eczema drug partnership with Kyowa Kirin involv...
Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amgen (AMGN) has just walked away from its licensing and co...
Amgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the atopi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
